|Mr. Steven M. Klosk||Pres, CEO & Director||2.21M||9.76M||1957|
|Mr. Gregory P. Sargen||Exec. VP of Corp. Devel. & Strategy and CFO||1.68M||670.27k||1966|
|Mr. Shawn P. Cavanagh||Exec. VP & COO||1.78M||1.46M||1966|
|Ms. Samantha M. Hanley||Sr. VP, Gen. Counsel & Corp. Sec.||918.25k||780.41k||1978|
|Ms. Alex Maw||Director of Marketing & Communications||N/A||N/A||N/A|
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Cambrex Corporation’s ISS Governance QualityScore as of October 4, 2019 is 2. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 2; Compensation: 5.